Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Thomas Budd

Showing results (101-110 of 103) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 103 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2024
Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus AnastrozoleJudith-Anne W Chapman, Jane Bayani, Sandip SenGupta, et al.
The Lancet. Oncology|June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trialWilliam D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2017
NCCN Guidelines Insights: Bone Cancer, Version 2.2017J Sybil Biermann, Warren Chow, Damon R Reed, et al.
Pageof 11

Showing results (101-110 of 103) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 103 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2024
Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus AnastrozoleJudith-Anne W Chapman, Jane Bayani, Sandip SenGupta, et al.
The Lancet. Oncology|June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trialWilliam D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2017
NCCN Guidelines Insights: Bone Cancer, Version 2.2017J Sybil Biermann, Warren Chow, Damon R Reed, et al.
Pageof 11